Những sự gián đoạn và quanh co trong đường cao tốc mô cơ tim và suy tim

Weber KT, Sun Y, Tyagi SC, Cleutjens JP: Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol 1994, 26:279–292. Geiger B, Bershadsky A, Pankov R, Yamada KM: Transmembrane crosstalk between the extracellular matrix—cy to skeleton crosstalk. Nat Rev Mol Cell Biol 2001, 2:793–805. Yurchenco PD, Schittny JC: Molecular architecture of basement membranes. FASEBJ 1990, 4:1577–1590. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422–433. Spinale FG, Zellner JL, Johnson WS, et al.: Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 1996, 28:1591–1608. Caulfield JB, Borg TK: The collagen network of the heart. Lab Invest 1979, 40:364–372. Campbell SE: Collagen Matrix in the Heart. New York: Springer-Verlag; 1995 JalilJE, Doering CW, Janicki JS, et al.: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. CirRes 1989, 64:1041–1050. SuttonMG, Sharpe N: Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981–2988. KatoS, Spinale FG, Tanaka R, et al.: Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995, 269:H863-H868. NwoguJI, Geenen D, Bean M, et al.: Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 2001, 104:2216–2221. AsifM, Egan J, Vasan S, et al.: An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci USA 2000, 97:2809–2813. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827–839. This is a comprehensive review regarding MMPs and tissue inhibitors of metalloproteinases and their pathophysiologic implications. CreemersEE, Cleutjens JP, Smits JF, Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001, 89:201–210. VanWart HE, Birkedal-Hansen H: The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990, 87:5578–5582. Hernandez-BarrantesS, Bernardo M, Toth M, Fridman R: Regulation of membrane type-matrix metalloproteinases. Semin Cancer Biol 2002, 12:131–138. McCawley LJ, Matrisian LM: Matrix metalloproteinases: they’re not just for matrix anymore! Curr Opin Cell Biol 2001, 13:534–540. GreeneJ, Wang M, Liu YE, et al.: Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996, 271:30375–30380. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267–283. This summary describes the evolution and structure of TIMPs and discusses the multiple functions of these molecules. RotenL, Nemoto S, Simsic J, et al.: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000, 32:109–120. KaiH, Ikeda H, Yasukawa H, et al.: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32:368–372. HojoY, Ikeda U, Ueno S, et al.: Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn CircJ 2001, 65:71–75. InokuboY, Hanada H, Ishizaka H, et al.: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am HeartJ 2001, 141:211–217. BradhamWS, Gunasinghe H, Holder JR, et al.: Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2002, 40:2165–2173. PetersonJT, Li H, Dillon L, Bryant JW: Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000, 46:307–315. Mukherjee R, Brinsa TA, Dowdy KB, et al.: Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 2003, 107:618–625. Wilson EM, Moainie SL, Baskin JM, et al.: Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003, 107:2857–2863. This is an elegant study of the regional and temporal changes in MMP and TIMP abundance after an MI. BaghelaiK, Marktanner R, Dattilo JB, et al.: Decreased expression of tissue inhibitor of metalloproteinase 1 in stunned myocardium. J Surg Res 1998, 77:35–39. LaviadesC, Varo N, Fernandez J, et al.: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998, 98:535–540. Li-Saw-HeeFL, Edmunds E, Blann AD, et al.: Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000, 75:43–47. HironoO, Fatema K, Nitobe J, et al.: Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol 2002, 39:195–204. LiH, Simon H, Bocan TM, Peterson JT: MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 2000, 46:298–306. MujumdarVS, Tyagi SC: Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 1999, 17:261–270. PetersonJT, Hallak H, Johnson L, et al.: Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 2001, 103:2303–2309. IwanagaY, Aoyama T, Kihara Y, et al.: Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J Am Coll Cardiol 2002, 39:1384–1391. TyagiSC, Campbell SE, Reddy HK, et al.: Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 1996, 155:13–21. ThomasCV, Coker ML, Zellner JL, et al.: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708–1715. SpinaleFG, Coker ML, Heung LJ, et al.: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102:1944–1949. KnauperV, Lopez-Otin C, Smith B, et al.: Biochemical characterization of human collagenase-3. J Biol Chem 1996, 271:1544–1550. Li YY, Feldman AM, Sun Y, McTiernan CF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98:1728–1734. Humphries MJ: Integrin structure. Biochem Soc Trans 2000, 28:311–339. Ross RS, Borg TK: Integrins and the myocardium. Circ Res 2001, 88:1112–1119. This is a summary of the structure and function of integrins in the myocardium and their role as signaling molecules. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673–687. Ross RS, Pham C, Shai SY, et al.: Beta1 integrins participate in the hypertrophic response of rat ventricular myocytes. Circ Res 1998, 82:1160–1172. GoldsmithEC, Carver W, McFaddenA, etal.: Integrin shedding as a mechanism of cellular adaptation during cardiac growth. Am J Physiol Heart Circ Physiol 2003, 284: H2227–2234. ZellnerJL, Spinale FG, Eble DM, et al.: Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 1991, 69:590–600. Sato H, Kinoshita T, Takino T, et al.: Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS Lett 1996, 393:101–104. Yana I, Weiss SJ: Regulation of membrane type-1 matrix metalloproteinase activation by proprotein convertases. Mol Biol Cell 2000, 11:2387–2401. OhuchiE, Imai K, Fujii Y, et al.: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997, 272:2446–2451. KnauperV, Will H, Lopez-Otin C, et al.: Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996, 271:17124–17131. StronginAY, Collier I, Bannikov G, et al.: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995, 270:5331–5338. TothM, Chvyrkova I, Bernardo MM, et al.: Pro-MMP-9 activation by the MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes. Biochem Biophys Res Commun 2003, 308:386–395. d’OrthoMP, Will H, Atkinson S, et al.: Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997, 250:751–757. RajavashisthTB, Xu XP, Jovinge S, et al.: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 1999, 99:3103–3109. HolmbeckK, Bianco P, Caterina J, et al.: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81–92. HolmbeckK, Bianco P, Yamada S, Birkedal-Hansen H: MT1-MMP: a tethered collagenase. J Cell Physiol 2004, 200:11–19. Deschamps AM, Yarbrough WM, Squires CE, et al.: Trafficking of the membrane type-1 matrix metalloproteinase (MT1-MMP) in ischemia and reperfusion: relation to interstitial MT1-MMP activity. Circulation 2005, In press. Seals DF, Courtneidge SA: The ADAMs family of metallo-proteases: multidomain proteins with multiple functions. Genes Dev 2003, 17:7–30. This is a comprehensive review of ADAM domain activity, cytokine and growth factor processing, and their role in human disease. KillarL, White J, Black R, Peschon J: Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann N Y Acad Sci 1999, 878:442–452. Black RA: Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 2002, 34:1–5. Satoh M, Nakamura M, Satoh H, et al.: Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis. J Am Coll Cardiol 2000, 36:1288–1294. Arndt M, Lendeckel U, Rocken C, et al.: Altered expression of ADAMs (A Disintegrin And Metalloproteinase) in fibrillating human atria. Circulation 2002, 105:720–725. Asakura M, Kitakaze M, Takashima S, et al.: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 2002, 8:35–40. Topper JN: TGF-beta in the cardiovascular system: molecular mechanisms of a context-specific growth factor. Trends Cardiovasc Med 2000, 10:132–137. RosenkranzS, Flesch M, Amann K, et al.: Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002, 283:H1253-H1262. SiguschHH, Campbell SE, Weber KT: Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. Cardiovasc Res 1996, 31:546–554. PintoYM, Pinto-Sietsma SJ, Philipp T, et al.: Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 rat. Hypertension 2000, 36:747–754. Torre-AmioneG, Kapadia S, Lee J, et al.: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996, 93:704–711. Sivasubramanian N, Coker ML, Kurrelmeyer KM, et al.: Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104:826–831. WeiCC, Meng QC, Palmer R, et al.: Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 1999, 99:2583–2589. CrawfordDC, Chobanian AV, Brecher P: Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994, 74:727–739. KawanoH, Do YS, Kawano Y, et al.: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101:1130–1137. Dell’ItaliaLJ, Meng QC, Balcells E, et al.: Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997, 100:253–258. SchiffrinEL, Intengan HD, Thibault G, Touyz RM: Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol 1997, 12:354–367. SecciaTM,Belloni AS, Kreutz R, et al.: Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003, 41:666–673. SaamT, Ehmke H, Haas C, et al.: Effect of endothelin blockade on early cardiovascular remodeling in the one-clip-two-kidney hypertension of the rat. Kidney Blood Press Res 2003, 26:325–332. WalkerCA, Baicu SC, Goldberg AT, et al.: Temporal endothelin dynamics of the myocardial interstitium and systemic circulation in cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000, 120:864–871.